FMP

FMP

Enter

RSLS - ReShape Lifesci...

photo-url-https://images.financialmodelingprep.com/symbol/RSLS.png

ReShape Lifesciences Inc.

RSLS

NASDAQ

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

0.339 USD

0.0005 (0.147%)

Historical Prices

From:

To:

0.3270.330.3350.340.3450.3509:36 AM09:53 AM10:15 AM10:37 AM10:55 AM11:13 AM11:30 AM11:46 AM12:00 PM12:14 PM12:27 PM12:43 PM01:04 PM01:38 PM01:59 PM02:21 PM02:36 PM02:53 PM03:12 PM03:35 PM03:53 PM

About

ceo

Mr. Paul F. Hickey

sector

Healthcare

industry

Medical - Devices

exchange

NASDAQ

Description

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion...

CIK

0001427570

ISIN

US76090R3093

CUSIP

761123603

Address

1001 Calle Amanecer

Phone

949 429 6680

Country

US

Employee

17

IPO Date

Oct 6, 2016

Financial Statement

-3M-2M-1M01M2M3M2023 Q42024 Q12024 Q22024 Q32024 Q4RevenueNet Income

Earnings

-70-60-50-40-30-20-1002023 Q22023 Q32023 Q42024 Q12024 Q22024 Q32024 Q42025 Q1EPS Consensus

RSLS Financial Summary

CIK

0001427570

Exchange

NASDAQ

Industry

Medical - Devices

Sector

Healthcare

CUSIP

761123603

ISIN

US76090R3093

Country

US

Price

0.34

Beta

1.93

Volume Avg.

15.75M

Market Cap

3.82M

Shares

-

52-Week

0.3-29

DCF

-9.2

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-0.02

P/B

-

Website

https://www.reshapelifesciences.com

Upgrades and Downgrades

We are unable to load the data!

fmp-logo

Latest RSLS News

Seeking Alpha

Aug 15, 2024

ReShape Lifesciences Inc. (RSLS) Q2 2024 Earnings Call Trans...

ReShape Lifesciences Inc. (NASDAQ:RSLS ) Q2 2024 Earnings Conference Call August 15, 2024 4:30 PM ET Company Participants Michael Miller - IR Paul Hickey - President and CEO Thomas Stankovich - CFO Krishna Gupta - Director, Vyome Therapeutics Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the ReShape Lifesciences Second Quarter 2024 Earnings Call.

GlobeNewsWire

Aug 13, 2024

ReShape Lifesciences® to Announce Financial Results for the ...

Conference Call to be Held at 4:30 pm ET on Thursday, August 15, 2024 Conference Call to be Held at 4:30 pm ET on Thursday, August 15, 2024

Seeking Alpha

May 17, 2024

ReShape Lifesciences, Inc. (RSLS) Q1 2024 Earnings Call Tran...

ReShape Lifesciences, Inc. (NASDAQ:RSLS ) Q1 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants Michael Miller - Investor Relatons Paul Hickey - President, CEO & Director Thomas Stankovich - CFO Conference Call Participants Operator Good afternoon, and thank you for joining the ReShape Lifesciences First Quarter 2024 Conference Call. I would like to turn the call over to Michael Miller from Rx Communications.

GlobeNewsWire

May 14, 2024

ReShape Lifesciences® to Announce Financial Results for the ...

IRVINE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the first quarter ended March 31, 2024, including a corporate update on Wednesday, May 15, 2024, after market.

PennyStocks

Dec 13, 2023

3 Penny Stocks Under $1 To Watch After December Fed Meeting

The wait is over for the results of the December 2023 FOMC Meeting and Fed press conference. If you had a Dovish Fed on your bingo card for this week, you might be ready to claim your prize.

InvestorPlace

Dec 13, 2023

Why Is ReShape Lifesciences (RSLS) Stock Up 68% Today?

ReShape Lifesciences (NASDAQ: RSLS ) stock is rising higher on Wednesday following approval from the Food and Drug Administration (FDA) for a PMA supplement. That a PMA supplement applies to the company's Lap-Band 2.0 FLEX.

Proactive Investors

Dec 13, 2023

ReShape Lifesciences stock soars as obesity treatment gets F...

ReShape Lifesciences (NASDAQ:RSLS) saw its stock soar, up 41% to 36 cents a share in premarket, after the micro-cap firm's latest obesity treatment, Lap-Band 2.0, was approved by the US Food and Drug Administration (FDA). The FDA provided the company with a PMA supplement approval for the new generation of ReShape's Lap-Band – described as a “minimally invasive alternative to surgical stapling procedures – which features ‘FLEX' technology that the company said acts as a ‘relief valve' allowing l...

GlobeNewsWire

Nov 6, 2023

ReShape Lifesciences® to Announce Financial Results for the ...

Conference Call to be Held at 5:00 pm ET on Wednesday, November 8, 2023 Conference Call to be Held at 5:00 pm ET on Wednesday, November 8, 2023

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep